Combination treatment for advanced stomach cancer after first therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of medications (IBI363 plus bevacizumab, with or without nab-paclitaxel) for people with advanced stomach cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth better than existing options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer (or cancer where the stomach meets the food pipe) that has grown or not responded well after your first treatment, which must have included immunotherapy.
- You are between 18 and 75 years old.
- You are able to take care of yourself (fully active or able to do light work) and are expected to live at least 3 more months.
- Your blood counts, liver and kidney function, and protein levels are within certain ranges (checked by blood tests before the study starts).
- You have at least one tumor that can be measured on a scan.
- You have not had certain heart problems, lung disease, or active infections, and you agree to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of two drugs (QL1706, which is an immunotherapy, and paclitaxel, a chemotherapy drug) plus a targeted drug called bevacizumab, for people with advanced stomach cancer that has grown despite a first treatment that included immunotherapy. It aims to see if 'rechallenging' with immunotherapy in a different combination can help control the cancer.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.